| Drug Name |
Degarelix |
| Drug ID |
BADD_D00599 |
| Description |
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. |
| Indications and Usage |
Degaralix is used for the management of advanced prostate cancer. |
| Marketing Status |
approved |
| ATC Code |
L02BX02 |
| DrugBank ID |
DB06699
|
| KEGG ID |
D08901
|
| MeSH ID |
C431566
|
| PubChem ID |
16136245
|
| TTD Drug ID |
D0Y7KH
|
| NDC Product Code |
55566-8403; 59651-477; 55566-8303 |
| UNII |
SX0XJI3A11
|
| Synonyms |
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide | uglypeptide1 | Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2 | Firmagon | degarelix | degarelix acetate | Gonax | FE 200486 | FE200486 | FE-200486 |
